



## The Role of Radiation in Cancer Treatment: New Insights towards Personalized Therapies

Guest Editors:

**Dr. Luigi Minafra**

National Research Council (CNR),  
Institute of Bioimaging and  
Molecular Physiology (IBFM),  
Cefalù, PA, Italy

**Dr. Francesco Paolo  
Cammarata**

National Research Council (CNR),  
Institute of Bioimaging and  
Molecular Physiology (IBFM),  
Cefalù, PA, Italy

**Dr. Marco Calvaruso**

National Research Council (CNR),  
Institute of Bioimaging and  
Molecular Physiology (IBFM),  
Cefalù, PA, Italy

Deadline for manuscript  
submissions:

**closed (15 December 2021)**

### Message from the Guest Editors

Dear Colleagues,

At present, radiation therapy (RT) remains an essential component of multimodality approaches for the treatment of many types of cancer, and one of the most effective cancer therapies. Currently, clinical practice still offers standard RT protocols for patients with cancer affecting the same organ, without considering the molecular profile and the tumoral histotype, which may affect the RT outcome. Unfortunately, RT does not always lead to therapeutic benefits, due to distant metastatic spread and local recurrence, which induce radioresistance. Indeed, tumor radiosensitivity depends on many factors, some of which are linked to the clinical state and genetic background of the patient. This Special Issue aims to provide new insights into the role of RT in different types of cancer in order to develop personalized therapies, and it will also highlight the use of combined approaches with new targeted agents. Other topics of interest to this Special Issue will be the discovery and analysis of radioresponse biomarkers reported by different in vitro, in vivo, or clinical studies.

Dr. Luigi Minafra

Dr. Francesco Paolo Cammarata

Dr. Marco Calvaruso

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer  
Institute, Winston-Salem, NC  
27103, USA  
2. Division of Hematologic  
Malignancies and Cellular  
Therapy, Duke University,  
Durham, NC 27710, USA

## Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM; ISSN 2075-4426)* is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

---

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[X@JPM\\_MDPI](https://twitter.com/JPM_MDPI)